For testing the susceptibility ofNeisseria gonorrhoeae to enoxacin, a proposed susceptibility category includes strains for which MICs are c0.5 ,ug/ml and zones of inhibition are .32 mm in diameter. Because of the sparcity of resistant gonococci, a resistance category was not defined, but laboratory-selected resistant mutants were appropriately categorized by the proposed criteria. Because the 110 N. gonorrhoeae stock cultures were all susceptible to c0.5 ,ug of enoxacin per ml, a resistant population could not be defined. Relatively resistant strains were developed in vitro by serial passages in the presence of subinhibitory concentrations of enoxacin, ciprofloxacin, or ofloxacin. All three selecting agents resulted in increased resistance to enoxacin, and that resistance was stable upon prolonged storage. This exercise provided 23 strains for which enoxacin MICs were .1.0 ,g/ml. Another resistant strain was obtained from a follow-up specimen from a patient treated with enoxacin. The enoxacin MIC for that strain was 2.0 ,ug/ml, although the initial strain was inhibited by 0.06 ,ug/ml. Although the patient was considered a bacteriologic failure, he was judged to be clinically cured.
Enoxacin (Parke-Davis, Ann Arbor, Mich.) is a fluoroquinolone antimicrobial agent. Its broad spectrum of antimicrobial activity includes penicillin-susceptible and penicillinresistant Neisseria gonorrhoeae as well as many other pathogens (1, 8) . A single oral dose of enoxacin has been successful in treating genital gonorrhea in males and females (7) . Agar dilution and disk diffusion susceptibility test procedures have been standardized for testing Neisseria gonorrhoeae isolates (4) (5) (6) . Those procedures utilize GC agar with an XV supplement devoid of cysteine and incubation in a moist atmosphere with 5 to 10% CO2. All other aspects of the test procedures are the same as those recommended by the National Committee for Clinical Laboratory Standards for testing nonfastidious species (5, 6) .
This report describes our efforts to standardize disk diffusion tests for evaluating enoxacin against N. gonorrhoeae. Interpretive criteria were proposed and then evaluated by correlating dilution test results with bacteriologic eradication and clinical cure rates gathered during early clinical trials. A multilaboratory study was also performed to define quality control limits for agar dilution and disk diffusion susceptibility tests.
MATERIALS AND METHODS
Agar dilution and disk diffusion susceptibility tests were performed exactly as outlined by the National Committee for Clinical Laboratory Standards (5, 6) for testing N. gonorrhoeae isolates. All tests were performed with GC agar containing a 1% defined XV supplement without cysteine and incubation at 35°C in 5 to 10% CO2.
Initial studies were performed with 110 N. gonorrhoeae stock cultures, which included 55 penicillin-susceptible strains, 27 penicillinase-producing strains, and 28 non-penicillinase-producing, penicillin-resistant strains. Susceptibility to Fig. 1 . All 110 strains were inhibited by .0. 5 .g/ml and produced zones of .33 mm in diameter. Additional data for selected variants for which MICs were .1.0 ,ug/ml are also included in the scattergram; all of the variants produced zones of c30 mm in diameter. One of those resistant strains was a posttherapy isolate from a patient, and the others were laboratory-selected mutants. The other clinical isolates represented the normal susceptible population of strains (MICs, <0.5 ,ug/ml; zones, >32 mm). The few strains for which MICs were .1.0 ,ug/ml or with zones of .31 mm differed from the normal population and thus could be categorized as being resistant, but whether that resistance actually predicted clinical resistance remains to be seen.
The clinical relevance of defining the susceptible MIC breakpoint as being .0.5 ,ug/ml was evaluated by reviewing data gathered from clinical trials ( Table 1) . Patients treated with a single 400-mg oral dose of enoxacin were the sources of 210 isolates for which MICs were available. These were not the isolates described in Fig. 1 . Of the 210 evaluable strains, 207 (99%) were inhibited by <0.25 ,ug/ml, and 97% of those susceptible strains were eradicated by enoxacin therapy. For the six susceptible strains that failed to respond bacteriologically the MICs were .0.125 ,ug/ml. Their failure to respond was probably related to factors other than bacterial resistance. The MIC for two strains was 1.0 p.g/ml, and both strains responded to therapy. The one strain for which the MIC was 4.0 ,ug/ml was not eradicated, although the patient was judged to be clinically cured.
Quality control limits for agar dilution susceptibility tests with supplemented GC agar were derived from the data in Table 2 . For tests on unsupplemented Mueller-Hinton agar (6) , the MICs for the S. aureus control strain (ATCC 29213) should be 1.0 ,ug/ml + one doubling dilution (0.5 to 2.0 ,ug/ml), and the same limits apply to tests on supplemented GC agar. For N. gonorrhoeae ATCC 49226, all MICs fell into a three-dilution range of 0.016 to 0.06 ,ug/ml, but there was skewing towards the lower end of that range ( Table 2) .
The results of replicate disk diffusion tests are shown in Table 3 . The control strain of S. aureus (ATCC 25923) should produce zones of 22 to 28 mm in diameter when tested on unsupplemented Mueller-Hinton agar (5 Interpretive criteria were difficult to select because of a sparcity of resistant strains. We propose that the normal susceptible population of gonococci should include those for which the MIC breakpoint is c0.5 jig/ml or the zone of inhibition is .32 mm. A review of clinical data confirmed that the isolates categorized as being susceptible to enoxacin by those criteria were indeed responsive to therapy (97% bacteriological eradication rates). There were not enough clinical isolates for which MICs were higher or zones were smaller to judge the clinical relevance of such in vitro test results. However, in vitro-selected mutants for which MICs were .1.0 jig/ml were not misidentified as being susceptible by tests with 10-jig enoxacin disks (zones, .31 mm). Further experience with enoxacin chemotherapy will be needed to determine whether the susceptible category can be extended to include strains for which MICs are higher or zones are smaller. At this time, there are too few resistant strains to make a reasonable judgment about whether the breakpoints should be adjusted upwards. The usefulness of enoxacin for treating gonococcal infections needs to be confirmed by extended clinical studies, but the current experiences are quite encouraging.
